P=N/A, N=400, Completed, Sohag University

We investigated whether DHED could prevent side effects associated with the aromatase inhibitor letrozole in a primate model of aging...Here, we show that a brain-selective estrogen therapy administered orally via the prodrug DHED substantially increases estrogen levels in the marmoset brain without affecting the periphery and normalizes impairments in working memory, hippocampal neuronal excitability and sleep induced by aromatase inhibition. These findings in a translational primate model represent a significant advance for women's health by positioning DHED as a non-invasive, safe and efficient novel hormone therapy to improve quality of life of women with ER+ breast cancers.

P3, N=309, Recruiting, University of California, San Francisco | Trial completion date: Mar 2026 --> Mar 2028 | Trial primary completion date: Mar 2026 --> Mar 2028

P4, N=62, Terminated, University of Washington | Recruiting --> Terminated; Study ended earlier than anticipated due to end of funding.

P2, N=70, Not yet recruiting, Kafrelsheikh University

MBR-01 may effectively mitigate abemaciclib-induced diarrhea, likely through the achievement of stabilization of gut microbiota composition. Larger prospective studies are warranted to validate these preliminary findings.

P3, N=200, Completed, Beni-Suef University | N=500 --> 200 | Trial completion date: Dec 2024 --> Apr 2026 | Trial primary completion date: Dec 2024 --> Mar 2026 | Not yet recruiting --> Completed

Meaningful overall survival benefit in hormone receptor-positive, HER2-negative breast cancer from adjuvant exemestane and/or OFS compared with tamoxifen alone is limited to high-risk premenopausal subgroups. Tamoxifen-based ET may not result in optimal outcomes in premenopausal high-grade HER2-negative tumours.

P2, N=178, Active, not recruiting, Dartmouth-Hitchcock Medical Center | Trial primary completion date: Apr 2025 --> Apr 2028

Positron emission tomography/computed tomography in January 2023 raised concern for recurrence, and exploratory laparoscopy in March 2023 documented peritoneal metastatic disease, followed by four cycles of cisplatin given within the then-prevailing carcinoma-based diagnostic framework...After external review, everolimus plus anastrozole was started in May 2025...At the most recent available follow-up in April 2026, the patient had no documented death and remained under postoperative surveillance. Discussion and This case illustrates the diagnostic importance of repeated tissue reassessment and the practical value of minimally invasive surgery as a relatively low-burden means of resection, restaging, and tissue acquisition in a rare molecularly reclassified adnexal tumor.

P1, N=75, Not yet recruiting, Northwestern University

Among the tested derivatives, compounds 6e and 6g exhibited significant cytotoxic activity against MCF-7 cells, with IC₅₀ values of 19.96 μM and 15.75 μM, respectively, demonstrating stronger activity than the reference drug cisplatin (21.42 μM). Molecular docking analysis demonstrated that the selected compounds exhibited binding interactions similar to letrozole within the aromatase active site. Based on combined cytotoxicity, enzyme inhibition, molecular docking, and ADME predictions, compound 6l emerged as the most promising candidate as a potential non-steroidal aromatase inhibitor.